ADVM - Adverum Biotechnologies, Inc.
After hours:
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.9600 |
| Open | 1.0000 |
| Bid | 0.9615 x 1400 |
| Ask | 0.9950 x 800 |
| Day's Range | 0.9357 - 1.0000 |
| 52 Week Range | 0.5310 - 1.8200 |
| Volume | |
| Avg. Volume | 400,558 |
| Market Cap | 99.811M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5200 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
Fair Value
Related Research
GlobeNewswireAdverum Biotechnologies Announces New Executive Leadership Roles
- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum’s clinical development, medical affairs and pharmacovigilance teams - REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announce
- GlobeNewswire
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California. Ixo-vec is currently being evaluated in the
- GlobeNewswire
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT administration of AAV-CFI using either the 7m8 or LSV1 capsid resulted in high expression levels and was well tolerated in non-human primates (NHPs) - - Presented data on an optogenetics program utilizing an engineered melanopsin mutant that could serve as a therapeutic transgene for optogenetic vis
- GlobeNewswire
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
- Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 - - LUNA 14-week data, including initial aflibercept protein levels anticipated in the third quarter 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new st
- GlobeNewswire
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that members of the executive team will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference being held on Wednesday, May 17, 2023 at 3:35 p.m. ET in New York, New York. The on-demand webcast fireside may be accessed un
- GlobeNewswire
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data will be presented during the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting being held May 16-20, 2023, in Los Angeles, California. At ASGCT 2023, Adverum will unveil new nonclinical data on the development of an IVT gene therap
- GlobeNewswire
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye - - Staggered administration of Ixo-vec in non-human primates (NHPs) showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral administration - - A no-observed-adverse-effect-level (NOAEL) in NHPs was ident
Simply Wall St.After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain
Key Insights Given the large stake in the stock by institutions, Adverum Biotechnologies' stock price might be...
- GlobeNewswire
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
- Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom - - Ixo-vec has also been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) - REDWOOD CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standar
- GlobeNewswire
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present an abstract featuring nonclinical data of Ixoberogene soroparvovec (Ixo-vec) for the treatment of neovascular age-related macular degeneration at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meet
ZacksIs Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
- GlobeNewswire
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
- Full enrollment of the LUNA trial anticipated in the second half of 2023 - - LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 - - LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - - Cash runway into 2025 - REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent o
- Simply Wall St.
Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Adverum Biotechnologies to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 12:50 p.m. ETOppenheimer 33rd
- GlobeNewswire
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On January 17, 2023, Adverum granted a new employee a stock option to purchase 150,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is m
- GlobeNewswire
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocul
- GlobeNewswire
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of participants supplemental injection free over two years across the 6x10^11 (6E11) and 2x10^11 (2E11) doses, respectively, regardless of
- GlobeNewswire
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California. End of stu
- GlobeNewswire
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision outcomes, as well as decreasing treatment burden by an 81-98% reduction in mean annualized anti-VEGF injections - The 2x10^11 vg/eye (2E11) dose meaningfully reduced fluid volume, including a 93% reduction in intraretinal (IRF) and 55% reduction in subretinal fluid (SRF) from baseline to week 48 -
- GlobeNewswire
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Richard Beckman, M.D., chief medical officer of Adverum Biotechnologies, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. The on-demand webcast corporate presentation may be
- GlobeNewswire
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under Events and Pr
- GlobeNewswire
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day a
ZacksAdverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
GlobeNewswireAdverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
LUNA Phase 2 Study in Wet AMD - Study Design Objective: The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 study evaluating a one-time IVT injection of either of two doses of Ixo-vec (ADVM-022), including 2x10^11 vg/eye (2E11) dose and a new, lower 6x10^10 vg/eye (6E10) dose in 72 patients. - LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring fr
- GlobeNewswire
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022. The on-demand webcast corporate presentation may be ac